In no other time in the history of pharmaceutical sciences has drug delivery played as many roles in bringing new therapies to patients as it is doing now. With the advent of combinatorial chemistry and high-throughput screening in drug discovery, the physicochemical properties of new drug candidates are such that the development of bioavailable dosage forms is becoming extremely difficult.
There are also major cellular barriers to overcome in targeting drugs to their sites of action. Additionally, drugs discovered based on genomic and other biotechnological research are difficult to deliver to their sites of action in therapeutically beneficial and commercially viable forms. Drug delivery is also playing major roles in the life-cycle management of older products.
There are also major cellular barriers to overcome in targeting drugs to their sites of action. Additionally, drugs discovered based on genomic and other biotechnological research are difficult to deliver to their sites of action in therapeutically beneficial and commercially viable forms. Drug delivery is also playing major roles in the life-cycle management of older products.
Services
Auritec Pharmaceuticals owns three classes of patents or exclusive licenses in the field of sustained release delivery: Versa intravaginal rings and implants The Plexis injectable sustained-release platform and Co-drug technologies. The Versa platform is Auritec's flagship technology. Using the Versa technology we developed the ganciclovir implant, Vitrasert and Retisert, the only FDA-approved antiviral drug delivery devices.
Auritec Pharmaceuticals looks for diseases or indications that have good drugs on the market, however the drugs have problems with their delivery. We are interested in safe and effective drugs that are nearing patent expiration and could benefit from an alternate delivery route. Sometimes treatment of the disease would benefit from local delivery, such as diseases in the eye.
Reviews
Be the first to review Auritec.
Write a Review
